Press coverage about CryoPort (NASDAQ:CYRX) has been trending somewhat positive on Saturday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CryoPort earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.3917242303124 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
CYRX has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on CryoPort from $6.00 to $8.50 and gave the company a “buy” rating in a report on Wednesday, July 26th. Janney Montgomery Scott set a $8.00 price objective on CryoPort and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, Cowen and Company lifted their price objective on CryoPort from $5.50 to $7.50 and gave the company an “outperform” rating in a report on Wednesday, August 9th.
CryoPort (NASDAQ CYRX) traded up $0.11 during mid-day trading on Friday, hitting $6.66. 59,800 shares of the stock were exchanged, compared to its average volume of 180,884. CryoPort has a 52 week low of $1.96 and a 52 week high of $10.40.
CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. CryoPort had a negative net margin of 91.28% and a negative return on equity of 46.99%. The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $2.84 million. sell-side analysts anticipate that CryoPort will post -0.32 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact CryoPort (CYRX) Stock Price” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-cryoport-cyrx-stock-price.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.